Characteristics of the first non-alcoholic fatty liver disease (NAFLD) cohort
| Total n=643 | Controls (stage F0) n=362 (56.3%) | Cases (stage F4) n=68 (10.6%) | Significance (p values) | |
| Characteristics | ||||
| Age (years) | 49±14 | 46±13 | 61±13 | <0.0001 |
| Sex (women) | 322 (50) | 165 (46) | 41 (60) | 0.026 |
| BMI (kg/m2) | 37±12 | 36±12 | 28±7 | <0.0001 |
| Diabetes mellitus (yes/no/NA, % yes) | 188/403/52 (32) | 84/265/13 (24) | 24/14/30 (63) | <0.0001 |
| Frequency of AAT genotypes | ||||
| Pi*MZ genotype | 36 (5.6) | 9 (2.5) | 9 (13.2) | <0.0001 |
| Pi*ZZ genotype | 0 (0) | 0 (0) | 0 (0) | NA |
| Pi*MS genotype | 29 (4.5) | 14 (3.9) | 3 (4.4) | 0.740* |
| Pi*SS genotype | 0 (0) | 0 (0) | 0 (0) | NA |
| Pi*SZ genotype | 0 (0) | 0 (0) | 0 (0) | NA |
Cases were defined as NAFLD patients with histological cirrhosis (stage F4), whereas controls were defined as NAFLD patients without histological evidence of fibrosis (stage F0). Quantitative measures are shown as mean±SD or as an absolute count (n) and relative frequency (%).
*Fisher’s exact test.
AAT, alpha1-antitrypsin; BMI, body mass index; NA, not available/applicable; Pi*MZ, heterozygous for the Pi*Z variant; Pi*ZZ, homozygous for the Pi*Z variant; Pi*MS, heterozygous for the Pi*S variant; Pi*SS, homozygous for the Pi*S variant; Pi*SZ, compound heterozygous for the Pi*S and the Pi*Z variant.